Prevention of transfusion-transmitted cytomegalovirus infections: Which is the optimal strategy?

Transfusion Medicine and Hemotherapy

Volumn 41, Issue 1, 2014, Pages 40-44

  Ziemann, Malte ^a   Hennig, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Blood donor; CMV; Human cytomegalovirus; Transfusion; Transfusion associated infections

Indexed keywords

VIRUS DNA;

BLOOD DONOR; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION PREVENTION; LEUKOPENIA; REVIEW; RISK ASSESSMENT; STRATEGIC PLANNING; TRANSFUSION TRANSMITTED CYTOMEGALOVIRUS INFECTION;

EID: 84928041321     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000357102     Document Type: Review

References (33)

1. Klemola E, Kaariainen L: Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med J 1965;6:1099-1102.
2. Hecker M, Qiu D, Marquardt K, et al: Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang 2004;86:41-44.
3. Ziemann M, Unmack A, Steppat D, et al: The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010;99:24-33.
4. Kääriäinen L, Klemola E, Paloheimo J: Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br Med J 1966;1:1270-1272.
5. Tolpin MD, Stewart JA, Warren D, et al: Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr 1985; 107:953-956.
6. Endresen K, Gjesdal K, Orstavik I, et al: Primary cytomegalovirus infection following open heart surgery. Acta Med Scand 1985;218:423-428.
7. Yeager AS, Grumet FC, Hafleigh EB, et al: Prevention of transfusion-Acquired cytomegalovirus infections in newborn infants. J Pediatr 1981;98: 281-287.
8. Bowden RA, Slichter SJ, Sayers M, et al: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-Associated CMV infection after marrow transplant. Blood 1995;86: 3598-3603.
9. Vamvakas EC: Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-Analysis. Transfus Med Rev 2005;19:181-199.
10. Schottstedt V, Blümel J, Burger R, et al: Human cytomegalovirus (HCMV)-Revised. Transfus Med Hemother 2010;37:365-375.
11. Thiele T, Krüger W, Zimmermann K, et al: Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011;51:2620-2626.
12. Nash T, Hoffmann S, Butch S, et al: Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion 2012; 52:2270-2272.
13. Wu Y, Zou S, Cable R, et al: Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2009;50:776-786.
14. Josephson CD, Castillejo M-I, Caliendo AM, et al: Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions. Transfus Med Rev 2011;25:125-132.
15. Funk M, Günay S, Volz-Zang C: Haemovigilance report of the Paul-Ehrlich-Institut 2010: Assessment of the Reports of Serious Adverse Transfusion Reactions pursuant to Section 63 c AMG (Arzneimittelgesetz, German Medicinal Products Act), 2012. Available at: www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/publikationen/haemovigilance-report-2010.pdf.
16. Zanghellini F, Boppana SB, Emery VC, et al: Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J Infect Dis 1999;180:702-707.
17. Ziemann M, Krueger S, Maier AB, et al: High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007;47:1972-1983.
18. Ziemann M, Heuft H-G, Frank K, et al: Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013;53:1088-1094.
19. Ziemann M, Juhl D, Görg S, Hennig H: The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013;53:2183-2189.
20. Zhang C, Buchanan H, Andrews W, et al: Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: Seroconversion and viral shedding. J Clin Virol 2006;35:338-342.
21. Drew WL, Tegtmeier G, Alter HJ, et al: Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003;43:309-313.
22. Dumont LJ, Luka J, VandenBroeke T, et al: The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001;97:3640-3647.
23. Kane RC, Rousseau WE, Noble GR, et al: Cytomegalovirus infection in a volunteer blood donor population. Infect Immun 1975:719-723.
24. Beneke JS, Tegtmeier GE, Alter HJ, et al: Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection. J Infect Dis 1984;150:883-888.
25. Foster KM, Jack I: A prospective study of the role of cytomegalovirus in post-transfusion mononucleosis. N Engl J Med 1969;280:1311-1316.
26. Gajewski JL, Johnson VV, Sandler SG, et al: A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112:3036-3047.
27. Diosi P, Moldovan E, Tomescu N: Latent cytomegalovirus infection in blood donors. Br Med J 1969;4:660-662.
28. Bayer WL, Tegtmeier GE: The blood donor: detection and magnitude of cytomegalovirus carrier states and the prevalence of cytomegalovirus antibody. Yale J Biol Med 1976;49:5-12.
29. Boeckh M, Gallez-Hawkins GM, Myerson D, et al: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997;64:108-113.
30. Emery VC, Sabin CA, Cope AV, et al: Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032-2036.
31. Kotton CN, Kumar D, Caliendo AM, et al: International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation 2010;89:779-795.
32. Roback JD, Drew WL, Laycock ME, et al: CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 2003;43: 14-321.
33. Drew WL, Roback JD: Prevention of transfusiontransmitted cytomegalovirus: reactivation of the debate Transfusion 2007;47:1955-1958.